07:00 , Oct 1, 2012 |  BioCentury  |  Finance

Valeant's eye chart

Valeant's eye chart With the acquisition of Visudyne verteporfin from QLT Inc. (TSX:QLT; NASDAQ:QLTI), Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) is once again betting it can resurrect an ophthalmic drug that had been left by...
00:56 , Oct 20, 2011 |  BC Extra  |  Financial News

Imagen eyes $40 million A round

Newco Imagen Biotech Inc. (New York, N.Y.) said it secured up to $40 million in a series A round from SV Life Sciences; Novo Ventures; and Fidelity Biosciences. Imagen is developing treatments for blinding diseases,...
07:00 , Aug 15, 2011 |  BC Week In Review  |  Company News

Gilead, Astellas infectious news

Gilead said FDA accepted the company's response to a warning letter issued last year over violations of cGMP regulations identified during an inspection of the company's San Dimas, Calif., manufacturing facility. Gilead said the issues...
07:00 , Jul 25, 2011 |  BC Week In Review  |  Clinical News

Macugen pegaptanib regulatory update

Pfizer withdrew an application to extend the label for Macugen pegaptanib in Europe to include visual impairment due to diabetic macular edema (DME). According to EMA, Pfizer made the decision after CHMP said the compound...
08:00 , Jan 10, 2011 |  BC Week In Review  |  Company News

PanOptica Inc. board of directors update

PanOptica Inc. , Mount Arlington, N.J.   Business: Ophthalmic   Appointed: Paul Chaney, co-founder, president and CEO of PanOptica; Lutz Giebel, managing partner at SV Life Sciences; David Guyer, partner at SV Life Sciences, and...
00:32 , Jan 5, 2011 |  BC Extra  |  Company News

PanOptica raises $30M, in-licenses ophthalmic compound

PanOptica Inc. (Mount Arlington, N.J.) raised $30 million in a series A round and in-licensed exclusive, worldwide rights to PAN-90806 from OSI Pharmaceuticals Inc. for ophthalmic indications. The small-molecule selective inhibitor of VEGF is in...
07:00 , Oct 25, 2010 |  BC Week In Review  |  Company News

Eyetech, SurModics deal

Eyetech and SurModics resumed development of an extended-release formulation of age-related macular degeneration (AMD) drug Macugen pegaptanib under a 2005 deal. SurModics will use its microparticles technology to develop the new formulation, after which Eyetech...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Clinical News

AmBisome amphotericin B regulatory update

Gilead received a warning letter from FDA related to violations of cGMP regulations identified during an inspection of the company's San Dimas, Calif. manufacturing facility earlier this year. The letter includes deficiencies in the manufacturing...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Clinical News

Cayston aztreonam lysine regulatory update

Gilead received a warning letter from FDA related to violations of cGMP regulations identified during an inspection of the company's San Dimas, Calif. manufacturing facility earlier this year. The letter includes deficiencies in the manufacturing...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Clinical News

Macugen pegaptanib regulatory update

Gilead received a warning letter from FDA related to violations of cGMP regulations identified during an inspection of the company's San Dimas, Calif. manufacturing facility earlier this year. The letter includes deficiencies in the manufacturing...